Decoding Novavax's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bullish stance on Novavax NVAX.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NVAX, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 22 uncommon options trades for Novavax.

This isn't normal.

The overall sentiment of these big-money traders is split between 63% bullish and 27%, bearish.

Out of all of the special options we uncovered, 3 are puts, for a total amount of $98,684, and 19 are calls, for a total amount of $1,215,783.

Latest Startup Investment Opportunities:

Predicted Price Range

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $5.0 to $15.0 for Novavax over the recent three months.

Volume & Open Interest Trends

Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Novavax's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novavax's whale trades within a strike price range from $5.0 to $15.0 in the last 30 days.

Novavax Call and Put Volume: 30-Day Overview

Largest Options Trades Observed:

About Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

In light of the recent options history for Novavax, it's now appropriate to focus on the company itself. We aim to explore its current performance.

Current Position of Novavax

• Trading volume stands at 4,420,130, with NVAX's price up by 1.39%, positioned at $13.14.
• RSI indicators show the stock to be is currently neutral between overbought and oversold.
• Earnings announcement expected in 25 days.

What Analysts Are Saying About Novavax

In the last month, 1 experts released ratings on this stock with an average target price of $18.0.

• Maintaining their stance, an analyst from B of A Securities continues to hold a Neutral rating for Novavax, targeting a price of $18.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novavax with Benzinga Pro for real-time alerts.